Question · asked by 1 review
N‐acetylcysteine (1200 mg) vs placebo: Acute chest syndrome (
- Population
- sickle cell disease
- Intervention
- N‐acetylcysteine (1200 mg)
- Comparison
- placebo
- Outcome
- Acute chest syndrome (
It is very uncertain whether N‐acetylcysteine (1200 mg) changes frequency of sickle cell‐related complications (acute chest syndrome) compared with placebo (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
N‐acetylcysteine (1200 mg) vs placebo Frequency of sickle cell‐related complications (acute chest syndrome) · sickle cell disease It is very uncertain whether N‐acetylcysteine (1200 mg) changes frequency of sickle cell‐related complications (acute chest syndrome) compared with placebo (very low certainty). Antioxidant supplementation for sickle cell disease (2024) · Cochrane Headline outcomes only | RR 5 [0.25, 101.48] | 1 study · 96 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antioxidant supplementation for sickle cell disease 2024 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.